Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Summary

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The companys product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

TABLE OF CONTENTS

2
List of Tables 4
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13
Licensing Agreements 13
AEMase Enters into Licensing Agreement with University of Texas at Austin 13
AECase Enters into Licensing Agreement with University of Texas at Austin 14
Equity Offering 15
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 15
Aeglea BioTherapeutics Raises USD54.8 million in IPO 16
Aeglea BioTherapeutics Inc - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 21
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 22
Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 24
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 26
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 28
Corporate Communications 29
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 29
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 30
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 31
Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 32
Product News 33
Nov 08, 2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 33
Product Approvals 34
May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 34
Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 35
Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 36
Clinical Trials 37
Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 37
Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 38
Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 39
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13
AEMase Enters into Licensing Agreement with University of Texas at Austin 13
AECase Enters into Licensing Agreement with University of Texas at Austin 14
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 15
Aeglea BioTherapeutics Raises USD54.8 million in IPO 16
Aeglea BioTherapeutics Inc, Key Competitors 18
Aeglea BioTherapeutics Inc, Key Employees 19
Aeglea BioTherapeutics Inc, Subsidiaries 20

List Of Figures

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Aeglea BioTherapeutics Inc (AGLE) - Financial and Strategic SWOT Analysis Review

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Strategic SWOT Analysis Review

FAQs